ArticleRespiratory research2026
National and provincial burden of interstitial lung disease mortality in China, 2013-2021: a nationwide analysis of trends and underlying cause of death.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe national and provincial epidemiological characteristics of interstitial lung disease (ILD) mortality remain unknown in China. To assess ILD mortality trends, causes, and regional disparities in China (2013–2021).
methodsAll death cases with ILD coded as the underlying cause or cause in any part of the cause of death chain from the National Mortality Surveillance System (NMSS) during 2013–2021 were included. Annual crude and age-standardized mortality rates (ASMR) were estimated by gender, age group, urban/rural, and province from 2013 to 2021. Joinpoint regression models were applied to calculate the average annual percentage change (AAPC) and corresponding 95% confidence intervals (CIs) in China during the study period. The distribution of different ILD subtypes with the broad category of ILD as the underlying cause of death was analyzed. We also analyzed the ranking of underlying cause of death for all ILD-associated deaths.
resultsIn 2021, the ASMR for ILD in China was 2.90/100,000 (95%CI: 2.84, 2.96), decreasing by 45.18% (AAPC: -7.65, 95% CI: -13.46, -1.45) compared with 2013 (5.29/100,000; 95%CI: 5.19, 5.39). Eighty percent of ILD deaths in China were 60 years or older. Nationally, ILD ASMR declined consistently across sexes, urban-rural divides, and eastern, central, and western regions during the study period. Among those who died with ILD in 2021, the top four underlying causes of death were other respiratory diseases (J98) (11.54%), sequelae of cerebrovascular disease (I69) (10.18%), other ILD (J84) (7.61%), and malignant neoplasm of bronchus and lung (C34) (7.01%).
conclusionsThe mortality burden of ILD stayed relatively high in males, those in economically developed regions, and the elderly. We recommend enhancing disease activity monitoring in high-risk groups or patients with specific ILD subtypes to lower mortality risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.